Login

Takami, Hiroshi

Treatment of Thyroid Tumor

Takami, Hiroshi - Treatment of Thyroid Tumor, ebook

198,25€

Ebook, PDF with Adobe DRM
ISBN: 9784431540496
DRM Restrictions

PrintingNot allowed
Copy to clipboardNot allowed

Table of contents

1. Introduction
Akira Yoshida

2. CQ1. What Are the Risk Factors for Thyroid Cancer?
Masahisa Saikawa, Haruki Akasu

3. CQ2. Is There a Difference in Prognosis Between Adult Thyroid Cancer and Juvenile Thyroid Cancer or Juvenile Follicular Cancer?
Masahisa Saikawa, Haruki Akasu

4. Column 1. Genetics of Thyroid Cancer
Masahisa Saikawa, Haruki Akasu

5. Column 2. Prevalence of Various Histological Types of Thyroid Cancer
Masahisa Saikawa, Haruki Akasu

6. Column 3. Anaplastic Transformation of Differentiated Carcinoma
Masahisa Saikawa, Haruki Akasu

7. Column 4. Incidence, Morbidity, and Mortality of Thyroid Carcinoma in Japan
Masahisa Saikawa, Haruki Akasu

8. CQ3. What Is the Frequency (Probability of Cancer Before Examination) of Thyroid Cancer
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

9. CQ4. What Are the Factors That Increase the Likelihood of Malignancy and What Is the Odds Ratio and Risk Ratio?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

10. CQ5. What Are the Physical Signs and Symptoms That Increase the Likelihood of Thyroid Cancer and What Are the Sensitivity and Specificity?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

11. CQ6. What Are the Imaging Studies Most Suitable for the Diagnosis of Thyroid Carcinoma and What Are Their Sensitivity, Specificity, and Likelihood Ratio?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

12. CQ7. What Are the Blood Chemistry Data That Increase the Likelihood of Thyroid Malignancy and What Are Their Sensitivity, Specificity, and Likelihood Ratio?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

13. CQ8. What Are the Sensitivity and Specificity of Aspiration Cytology?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

14. CQ9. What Are the Sensitivity and Specificity of Ultrasonography, CT, MRI, Laryngoscopy, and Bronchoscopy in the Preoperative Evaluation of Thyroid Cancer Invasion to the Trachea, Esophagus, and the Recurrent Laryngeal Nerve?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

15. CQ10. How Is the Natural History of Nodules Diagnosed as Benign (Growth and Reduction Rates)?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

16. CQ11. Does TSH Suppression Therapy Reduce the Size of Tumors Diagnosed as Benign?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

17. CQ12. What Is the Intra-Observer Variation in the Pathological Diagnosis of Follicular Carcinoma?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

18. CQ13. What Is the Efficacy of Percutaneous Ethanol Injection Therapy for Autonomously Functioning Thyroid Nodules?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

19. CQ14. Do Cystic Nodules Decrease in Volume by Aspiration and Drainage of Content Fluid and Percutaneous Ethanol Injection Therapy?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

20. CQ15. What Is the Likelihood That Multinodular Goiter Will Be Surgically Resected After Observation?
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

21. Column 5. Indication for Surgery of Nodular Goiter
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

22. Column 6. Diagnosis of Anaplastic Carcinoma
Shinichi Suzuki, Nobuhiro Fukunari, Kaori Kameyama, Megumi Miyakawa, Katsuhiro Tanaka, Yatsuka Hibi

23. CQ16. What Is the Most Appropriate and Convenient Risk Classification System for Predicting the Prognosis of Patients with Papillary Carcinoma?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

24. CQ17. Does Total (or Near Total) Thyroidectomy Improve the Prognosis of Papillary Carcinoma Patients Compared to Lobectomy or Lobectomy Isthmectomy?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

25. CQ18. Does Central Compartment Dissection Improve the Prognosis of Papillary Carcinoma Patients?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

26. CQ19. Does Dissection of the Lateral Compartment Improve the Prognosis of Papillary Carcinoma Patients?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

27. CQ20. When Can Papillary Microcarcinoma (Papillary Carcinoma Measuring 1 cm or Less) Be Observed Without Immediate Surgery?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

28. Column 7. What Is the Acceptable Incidence for Persistent Recurrent Laryngeal Nerve Paralysis and Persistent Hypoparathyroidism as Complications of Thyroid Surgery?
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

29. Column 8. The Controversy Regarding the Extent of Thyroidectomy for Papillary Carcinoma and Actual Practice in Japan
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

30. Column 9. Lobectomy and Paratracheal Node Dissection
Tsuneo Imai, Hiroya Kitano, Iwao Sugitani, Nobuyuki Wada

31. Introduction
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

32. CQ21. Is It Possible to Diagnose Follicular Carcinoma on Preoperative FNA or Intraoperative Frozen Section Diagnosis?
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

33. CQ22. Does Classification of Follicular Carcinoma According to the Degree of Invasiveness (Widely Invasive and Minimally Invasive Types) Reflect the Prognosis?
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

34. CQ23. When Is Completion Total Thyroidectomy Recommended as a Second Surgery for Patients Who Underwent Hemithyroidectomy and Were Diagnosed as Having Follicular Carcinoma on Postoperative Pathological Examination?
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

35. CQ24. Does Total Thyroidectomy with Radioactive Iodine Ablation and TSH Suppression Therapy Improve Patient Prognosis with Widely Invasive Follicular Carcinoma Compared to Only Limited Thyroidectomy?
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

36. CQ25. Does Prognosis of Oxyphilic (Hurthle Cell) Follicular Carcinoma Differ from That of Conventional Follicular Carcinoma?
Kaoru Kobayashi, Akira Yoshida, Takehito Igarashi

37. CQ26. What Is the Usefulness of RET Gene Mutation Analysis for Medullary Carcinoma?
Shinya Uchino, Daishu Miura, Takahiro Okamoto

38. CQ27. What Are the Incidences of Diseases Associated with Hereditary Medullary Carcinoma?
Shinya Uchino, Daishu Miura, Takahiro Okamoto

39. CQ28. Do Total Thyroidectomy and Lymph Node Dissection for Sporadic and Hereditary Medullary Carcinoma Improve the Prognosis?
Shinya Uchino, Daishu Miura, Takahiro Okamoto

40. CQ29. Is Chemotherapy Effective for Advanced or Relapsed Medullary Carcinoma?
Shinya Uchino, Daishu Miura, Takahiro Okamoto

41. CQ30. What Are Prognostic Factors of Medullary Carcinoma?
Shinya Uchino, Daishu Miura, Takahiro Okamoto

42. CQ31. What Is the Definition of Poorly Differentiated Carcinoma? What Is Its Prevalence and Prognosis?
Yasuhiro Ito, Hiroshi Kanma

43. CQ32. Can Poorly Differentiated Carcinoma Be Diagnosed Preoperatively?
Yasuhiro Ito, Hiroshi Kanma

44. CQ33. Do Total Thyroidectomy and Prophylactic Lymph Node Dissection Improve the Prognosis of Patients with Poorly Differentiated Carcinoma?
Yasuhiro Ito, Hiroshi Kanma

45. CQ34. Does Additional Surgery Improve the Prognosis of Patients Who Underwent Hemithyroidectomy Under a Diagnosis of Papillary or Follicular Carcinoma, But Who Are Later Diagnosed as Having Poorly Differentiated Carcinoma on Postoperative Pathological Examination?
Yasuhiro Ito, Hiroshi Kanma

46. CQ35. Do Therapies Other Than Surgery Improve the Prognosis for Patients with Poorly Differentiated Carcinoma?
Yasuhiro Ito, Hiroshi Kanma

47. Column 10. Carcinoma Showing Thymus-Like Differentiation/Intrathyroidal Epithelial Thymoma
Yasuhiro Ito, Hiroshi Kanma

48. Introduction
Kiminori Sugino, Naoyoshi Onoda

49. CQ36. Does Surgical Treatment for Anaplastic Carcinoma Improve Prognosis?
Kiminori Sugino, Naoyoshi Onoda

50. CQ37. Do Adjuvant Therapies Improve the Prognosis of Anaplastic Carcinoma in Patients Who Underwent Curative Surgery?
Kiminori Sugino, Naoyoshi Onoda

51. CQ38. Does Combined Modality Therapy for Anaplastic Carcinoma Improve Prognosis?
Kiminori Sugino, Naoyoshi Onoda

52. CQ39. Should Relapsed Lesions of Differentiated Carcinoma That Were Diagnosed as Anaplastic Carcinoma Be Treated as Anaplastic Carcinoma?
Kiminori Sugino, Naoyoshi Onoda

53. Column 11. When Should Palliative Care Be Considered? Is the Prognosis Explained to Patients?
Kiminori Sugino, Naoyoshi Onoda

54. Column 12. Squamous Cell Carcinoma of the Thyroid Is Currently Classified as a Different Histology from Anaplastic Carcinoma. Are Therapeutic Strategies and Prognosis of Squamous Cell Carcinoma Similar to Those of Anaplastic Carcinoma?
Kiminori Sugino, Naoyoshi Onoda

55. CQ40. What Are Applications and Roles of Ablation?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

56. CQ41. Is Iodine Restriction Necessary Before Ablation?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

57. CQ42. What Is the Appropriate Dose of 131I?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

58. CQ43. What Is the Benefit of RAI Therapy for Local Recurrence, Lymph Node Metastasis and Distant Metastasis of Differentiated Thyroid Carcinoma?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

59. CQ44. What Is the Application, Effect and Safety of Recombinant Human Thyroid Stimulating Hormone (rhTSH)?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

60. Column 13. Comments on RAI Therapy Including the Actual Situation in Japan
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

61. Column 14. Applications for External Beam Radiotherapy for Differentiated Thyroid Carcinoma
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

62. Column 15. Is it Appropriate to 131I Scintigraphy Before RAI Therapy? What Is the Dose?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

63. Column 16. What Is the Actual Status of Radiotherapy (External Beam Radiotherapy and 131I MIBG Therapy)?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

64. Column 17. What Are the Side Effects of RAI Therapy and What Is Their Frequency?
Seigo Kinuya, Naoyuki Shigematsu, Yasushi Noguchi, Tatsuya Higashi

65. CQ45. What Is the Indication for Resection of the Recurrent Laryngeal Nerve for Cases Extending There?
Hiroyuki Iwasaki, Wataru Kitagawa

66. CQ46. Is Phonetic Function Improved by Reconstruction of the Recurrent Laryngeal Nerve?
Hiroyuki Iwasaki, Wataru Kitagawa

67. CQ47. For Cases Extending to the Trachea, Does Sleeve Resection of the Trachea Improve the Survival Rate Compared to Partial Resection (Wedge Resection or Window Resection)?
Hiroyuki Iwasaki, Wataru Kitagawa

68. CQ48. Does Tracheal Resection Improve the Survival Rate Compared with No Resection?
Hiroyuki Iwasaki, Wataru Kitagawa

69. Column 18. Treatment and Management Approaches for Cases Extending to the Trachea with Larynx, Esophagus, or Mediastinum Involvement
Hiroyuki Iwasaki, Wataru Kitagawa

70. CQ49. Does TSH Suppression Therapy After Surgery for Differentiated Thyroid Carcinoma Improve Survival?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

71. CQ50. Is Serum Thyroglobulin Measurement Useful as a Marker of Carcinoma Recurrence After Surgery?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

72. CQ51. Are Measurements of Calcitonin and CEA Useful as Markers of Recurrence After Surgery for Medullary Carcinoma?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

73. CQ52. What Are Useful Imaging Studies to Detect Lesions of Recurrence for Medullary Carcinoma with Elevation of Postoperative Calcitonin Level?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

74. CQ53. Is Chemotherapy for Advanced Thyroid Carcinoma Effective?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

75. CQ54. Is Percutaneous Ethanol Injection Therapy Effective for Local or Lymph Node Recurrence and Bone Metastasis?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

76. CQ55. Are Alternate Therapies Effective for Thyroid Carcinoma?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

77. Column 19. How Long Should Patients with Differentiated Thyroid Carcinoma Be Followed After Surgery?
Minoru Fujimori, Hisato Hara, Hidemitsu Tsutsui

Keywords: Medicine & Public Health, Oncology, Endocrinology, Surgery

Author(s)
 
 
 
 
Publisher
Springer
Publication year
2013
Language
en
Edition
2013
Page amount
328 pages
Category
Medicine, Health Care, Mode
Format
Ebook
eISBN (PDF)
9784431540496

Similar titles